ARTICLE | Clinical News
APD668: Phase I started
February 13, 2006 8:00 AM UTC
JNJ's subsidiary, Ortho-McNeil Pharmaceutical Inc. (Raritan, N.J.), started a double-blind, placebo-controlled, dose-escalation Phase I trial in healthy volunteers. The start of the trial triggered a...